Karl Naegler joined Ventech in 2009 and is a General Partner in the Life Sciences sector. He brings to Ventech his international investor experience in the life science sector. Karl sits on the Boards of ActoGenix and Covagen.
Prior to joining Ventech he worked with Atlas Venture (London and Munich) for close to eight years, where he was instrumental for the formation and financing of several start ups across Europe. He notably worked closely with U3 Pharma, prior to its acquisition by Daiichi Sankyo Co., Ltd. in 2008 and served on the boards of Nitec Pharma and Lumavita.
Previously, he worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg, France. Karl obtained his PhD for his work in the area of molecular neurobiology at the Max-Delbrück-Center for Molecular Medicine Berlin. Karl holds an MSc in Biology from the Free University of Berlin and prepared his thesis at Monash University in Melbourne, Australia. During his successful academic career he contributed to several publications in highly respected scientific journals, including Science and FASEB.
